Angelos Stergiou: FDA and EMA Orphan Drug Designation for WT1 Vaccine
Dr. Angelos Stergiou, MD, ScD h.c. is an international scientist and physician whose positions of increasing responsibility with biotechnology and pharmaceutical companies have allowed him to build a strong reputation. In 2012, he founded SELLAS Life Sciences Group to further his reputation and contributions to society through drug development. As of 2016, SELLAS Life Sciences Group’s WT1 cancer vaccine received FDA and EMA Orphan Drug Designation and is entering Phase 3 studies.
The FDA Orphan Drug Designation SELLAS Life Sciences Group to further develop and market the WT1 Vaccine. It is designed for drugs that treat rare diseases and, since 1983, it has helped over 400 products progress and help patients. The WT1 vaccine is among those drugs to receive the orphan designation.
· About the WT1 Cancer Vaccine. SELLAS Life Sciences Group’s WT1 cancer vaccine is a late-stage immunotherapy drug that targets solid tumors and hematologic cancers. The vaccine targets an antigen — known as the WT1 antigen — that is found in a large number of cancers, but is rarely expressed in healthy adult cells.
By training the body’s immune system to seek and destroy the WT1 antigen, the vaccine is able to improve immune response and to provide ongoing aid with recurring tumors. The WT1 cancer vaccine has the potential to target more than twenty types of cancers that are known to express the WT1 antigen.
To follow the progress of SELLAS Life Sciences Group and of Dr. Angelos M. Stergiou, MD, keep your eye on the news for information about the WT1 cancer vaccine.